# US 2023/0054250 A1 · Non-aqueous sustained release drug delivery system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054250 A1
- Document ID: US20230054250A1
- Status: Published application
- Kind: A1
- Application number: 17/792,499
- Filed: 2021-01-14
- Published: 2023-02-23
- Earliest claimed: 2020-01-14
- Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Inventors: Yong GAN; Shiyan GUO; Yinyin SUN
- Web page: https://patentgrep.com/patent/US20230054250A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4748: forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A non-aqueous sustained release drug delivery system, which contains, based on the total weight of the sustained release drug delivery system, about 0.1-20% of an active agent, about 0.5-50% of a drug solvent, about 1-98% of a drug sustained release agent, about 0.1-85% of a drug solubilizer, about 0.1-10% of an efficacy enhancer, about 0-1% of an antioxidant, and about 0-8% of an acid-base regulator. The non-aqueous sustained release drug delivery system can yield an improved sustained release effect, improve bioavailability, and enhance the therapeutic effect.

## Claims

### Claim 1

A non-aqueous sustained release drug delivery system, comprising: an active agent, a drug solvent, a drug sustained release agent, a drug solubilizer, an efficacy enhancer, an optional antioxidant, and an optional acid-base regulator, wherein,
the drug solvent is one or more selected from the group consisting of benzyl alcohol, ethanol, glycerol, isopropanol, liquid polyethylene glycol, polyethylene glycol monomethyl ether, glycerol monoacetate, diethylene glycol monoethyl ether, ethyl lactate, tetrahydrofuran polyethylene glycol ether, benzyl benzoate, dimethyl acetamide, N-methyl pyrrolidone, 2-pyrrolidone, propylene glycol, methyl acetate, ethyl acetate, propylene glycol diacetate, diethyl malonate, glyceryl triacetate, dimethylformamide, dimethyl sulfoxide, caprolactam, triethyl citrate, and propylene carbonate,
the drug sustained release agent is one or more selected from the group consisting of biodegradable polymers and pharmaceutical oils,
the drug solubilizer is one or more selected from the group consisting of pharmaceutical surfactants,
the efficacy enhancer is one or more selected from the group consisting of ω-3 fatty acids and metabolites thereof, substances rich in ω-3 fatty acids or metabolites thereof, glucocorticoids, and phosphodiesterase-4 inhibitors,
the antioxidant is one or more selected from the group consisting of cysteine, α-tocopherol, α-tocopherol acetate, N-acetyl-L-cysteine, butylated hydroxyanisole, dibutylated hydroxytoluene, propyl gallate, tert-butyl hydroquinone, lipoic acid, tea polyphenols, L-ascorbyl palmitate, glutathione, and
the acid-base regulator is one or more selected from the group consisting of arginine, lysine, histidine, glycine, tromethamine, diethanolamine, ethylenediamine, meglumine, hydrochloric acid, acetic acid, anhydrous citric acid, ascorbic acid, lactic acid, tartaric acid, methanesulfonic acid, methionine, sodium hydroxide, and triethanolamine.

### Claim 2 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, comprising:
based on the total weight of the sustained release drug delivery system, in weight percentage,
0.1% to 20% of the active agent;
0.5% to 50% of the drug solvent;
1% to 98% of the drug sustained release agent;
1% to 85% of the drug solubilizer;
0.1% to 10% of the efficacy enhancer;
0% to 1% of the optional antioxidant; and
0% to 8% of the optional acid-base regulator.

### Claim 3 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1 wherein, the active agent includes at least one of: anticancer drugs, anti-inflammatory drugs, anti-infective drugs, painkillers, hormones, anti-diabetic drugs, anti-hypertension drugs, anti-AIDS drugs, immune enhancers, anti-viral drugs, cardiotonics, anti-obesity drugs, bone metabolism regulators, antiepileptics, anticonvulsants, antidepressants, antipsychotics, anti-Parkinson’s disease drugs, urinary tract drugs, contraceptives, anti-osteoporosis drugs, protein assimilation agents, smoking cessation aids, and cell adhesion promoters.

### Claim 4 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein the drug sustained release agent is one or more selected from the group consisting of pharmaceutical oils.

### Claim 5 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein,
the biodegradable polymer is one or more selected from the group consisting polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), polyorthoesters, sucrose acetate iso-butyrate, glycerin fatty acid ester, PEGylated PLA/PLGA, PLGA-PEG-PLGA copolymer, triethylene glycol poly(orthoester) polymer, chitosan, water-soluble carboxymethyl chitosan, fibroin, poly-β-hydroxybutyrate valerate, polylactide/lactide-polyethylene glycol copolymer, polylactide/lactide-polyethylene glycol blend, polycaprolactone-polyethylene glycol copolymer, blend of poly β-hydroxybutyrate and polyethylene glycol, and blend of polylactic acid/hydroxyacetic acid,
the pharmaceutical oil is one or more selected from the group consisting of castor oil, sesame oil, soybean oil, sunflower seed oil, peanut oil, corn oil, rapeseed oil, olive oil, cotton seed oil or other natural vegetable oils, semi-natural oils artificially modified from natural vegetable oils, purified oils and corresponding derivatives; and synthetic oils, including medium chain triglycerides with a carbon chain length of C6-C12, long chain triglycerides with a carbon chain length of C13-C24, triacetin or other corresponding derivatives, and ethyl oleate,
the pharmaceutical surfactant is one or more selected from the group consisting of pharmaceutical phospholipids, polyoxyl 15 hydroxystearate, polysorbate, polyoxyethylene castor oil, poloxamer, polyoxyethylene fatty acid ester, phosphatidylcholine phosphatidylglycerol, polyethylene glycol, polyethylene glycol monomethyl ether, gelatin,
the ω-3 fatty acids and metabolites thereof is one or more selected from the group consisting of ω-3 polyunsaturated fatty acids and metabolites thereof,
the substances rich in ω-3 fatty acids or metabolites thereof is one or more selected from the group consisting of substances rich in α-linolenic acid, substances rich in α-linolenic acid metabolites,
the glucocorticoids is one or more selected from the group consisting of prednisone, methylprednisone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, and combinations thereof, and
the phosphodiesterase-4 inhibitors is one or more selected from the group consisting of roflumilast, rolipram, penntoxifylline, and combinations thereof.

### Claim 6 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein,
the drug sustained release agent is one or more selected from the group consisting of castor oil, sesame oil, ethyl oleate, soybean oil, medium chain triglyceride, and peanut oil, the pharmaceutical surfactant is one or more selected from the group consisting of pharmaceutical phospholipids,
the ω-3 polyunsaturated fatty acids is one or more selected from the group consisting of α-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and combinations thereof,
the substance rich in α-linolenic acid is one or more selected from the group consisting of linseed oil, perilla seed oil, walnut oil, argan oil, or combinations thereof,
the substance rich in α-linolenic acid metabolites is one or more selected from the group consisting of fish oil, laver oil, algal oil, and combinations thereof.

### Claim 7 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein the substance rich in ω-3 fatty acids or metabolites thereof is one or more selected from the group consisting of substances rich in ω-3 fatty acids or metabolites thereof with eicosapentaenoic acid content of not less than 15% and docosahexaenoic acid content of not less than 10%.

### Claim 8 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein the system is administered by injection or by other forms of external administration.

### Claim 9 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein the release duration of the active agent in the drug delivery system reaches at least 12 h.

### Claim 10 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein a total amount administered per day of the sustained release drug delivery system is 1 to 1000 mg of the active drug.

### Claim 11 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, comprising:
based on the total weight of the sustained release drug delivery system, in weight percentage,
0.5% to 15% of the active agent;
2% to 40% of the drug solvent;
5% to 90% of the drug sustained release agent;
5% to 80% of the drug solubilizer;
1% to 10% of the efficacy enhancer;
0% to 0.5% of the antioxidant; and
0% to 5% of the acid-base regulator.

### Claim 12 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, comprising:
based on the total weight of the sustained release drug delivery system, in weight percentage,
1% to 10% of the active agent;
5% to 35% of the drug solvent;
10% to 82% of the drug sustained release agent;
10% to 65% of the drug solubilizer;
2% to 8% of the efficacy enhancer;
0% to 0.3% of the antioxidant; and
0% to 2% of the acid-base regulator.

### Claim 13 (depends on 6)

The non-aqueous sustained release drug delivery system according to claim 6, wherein,
the drug sustained release agent is one or more selected from the group consisting of castor oil, soybean oil, and sesame oil,
the pharmaceutical phospholipids is one or more selected from the group consisting of natural phospholipids, semi-synthetic phospholipids, and synthetic phospholipids, and
the α-linolenic acid is the α-linolenic acid (ALA) of plant origin.

### Claim 14 (depends on 13)

The non-aqueous sustained release drug delivery system according to claim 13, wherein,
the natural phospholipids is one or more selected from the group consisting of egg yolk lecithin, soybean lecithin, and combinations thereof,
the semi-synthetic phospholipids is one or more selected from the group consisting of hydrogenated egg yolk lecithin, hydrogenated soybean phospholipids or combinations thereof, and
the synthetic phospholipids is one or more selected from the group consisting of dipalmitoyl phosphatidylethanolamine, dipalmitoyl phosphatidic acid,
dipalmitoylphosphatidylglycerole, dioleoylphosphatidylethanolamine,
dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine, and combinations thereof.

### Claim 15 (depends on 7)

The non-aqueous sustained release drug delivery system according to claim 7, wherein the substance rich in ω-3 fatty acids or metabolites thereof is one or more selected from the group consisting of substances rich in ω-3 fatty acids or metabolites thereof with eicosapentaenoic acid content of not less than 20% and docosahexaenoic acid content of not less than 10%.

### Claim 16 (depends on 7)

The non-aqueous sustained release drug delivery system according to claim 7, wherein the substance rich in ω-3 fatty acids or metabolites thereof is one or more selected from the group consisting of fish oil and laver oil.

### Claim 17 (depends on 8)

The non-aqueous sustained release drug delivery system according to claim 8, wherein the injection administration includes at least one of subcutaneous, intradermal, intramuscular injection administration, direct instillation at the incision, incision infiltration administration, administration at the nerve plexus, injection at articular cavity, and intraocular administration.

### Claim 18 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein a release duration of the active agent in the drug delivery system reaches at least 24 h.

### Claim 19 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein a release duration of the active agent in the drug delivery system reaches at least 48 h.

### Claim 20 (depends on 1)

The non-aqueous sustained release drug delivery system according to claim 1, wherein a release duration of the active agent in the drug delivery system reaches at least 72 h.
